Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer

DM. O'Malley, T. Myers, P. Wimberger, T. Van Gorp, A. Redondo, D. Cibula, S. Nicum, M. Rodrigues, FJ. Backes, JN. Barlin, SN. Lewin, P. Lim, B. Pothuri, E. Diver, S. Banerjee, D. Lorusso

. 2024 ; 20 (32) : 2423-2436. [pub] 20240731

Language English Country England, Great Britain

Document type Journal Article, Clinical Trial Protocol

Persistent link   https://www.medvik.cz/link/bmc25004200

Grant support
ImmunoGen

At first recurrence, platinum-sensitive ovarian cancer (PSOC) is frequently treated with platinum-based chemotherapy doublets plus bevacizumab, then single-agent bevacizumab. Most patients' disease progresses within a year after chemotherapy, emphasizing the need for novel strategies. Mirvetuximab soravtansine-gynx (MIRV), an antibody-drug conjugate, comprises a folate receptor alpha (FRα)-binding antibody and tubulin-targeting payload (maytansinoid DM4). In FRα-high PSOC, MIRV plus bevacizumab previously showed promising efficacy (objective response rate, 69% [95% CI: 41-89]; median progression-free survival, 13.3 months [95% CI: 8.3-18.3]; median duration of response, 12.9 months [95% CI: 6.5-15.7]) and safety. The Phase III randomized GLORIOSA trial will evaluate MIRV plus bevacizumab vs. bevacizumab alone as maintenance therapy in patients with FRα-high PSOC who did not have disease progression following second-line platinum-based doublet chemotherapy plus bevacizumab.Clinical Trial Registration: ClinicalTrials.gov ID: NCT05445778; GOG.org ID: GOG-3078; ENGOT.ESGO.org ID: ENGOT-ov76.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25004200
003      
CZ-PrNML
005      
20250206110012.0
007      
ta
008      
250121s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/14796694.2024.2372241 $2 doi
035    __
$a (PubMed)39082675
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a O'Malley, David M $u Gynecologic Oncology, James Cancer Center/The Ohio State University, Columbus, OH 43210, USA $1 https://orcid.org/0000000228280177
245    10
$a Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer / $c DM. O'Malley, T. Myers, P. Wimberger, T. Van Gorp, A. Redondo, D. Cibula, S. Nicum, M. Rodrigues, FJ. Backes, JN. Barlin, SN. Lewin, P. Lim, B. Pothuri, E. Diver, S. Banerjee, D. Lorusso
520    9_
$a At first recurrence, platinum-sensitive ovarian cancer (PSOC) is frequently treated with platinum-based chemotherapy doublets plus bevacizumab, then single-agent bevacizumab. Most patients' disease progresses within a year after chemotherapy, emphasizing the need for novel strategies. Mirvetuximab soravtansine-gynx (MIRV), an antibody-drug conjugate, comprises a folate receptor alpha (FRα)-binding antibody and tubulin-targeting payload (maytansinoid DM4). In FRα-high PSOC, MIRV plus bevacizumab previously showed promising efficacy (objective response rate, 69% [95% CI: 41-89]; median progression-free survival, 13.3 months [95% CI: 8.3-18.3]; median duration of response, 12.9 months [95% CI: 6.5-15.7]) and safety. The Phase III randomized GLORIOSA trial will evaluate MIRV plus bevacizumab vs. bevacizumab alone as maintenance therapy in patients with FRα-high PSOC who did not have disease progression following second-line platinum-based doublet chemotherapy plus bevacizumab.Clinical Trial Registration: ClinicalTrials.gov ID: NCT05445778; GOG.org ID: GOG-3078; ENGOT.ESGO.org ID: ENGOT-ov76.
650    _2
$a lidé $7 D006801
650    12
$a bevacizumab $x aplikace a dávkování $x terapeutické užití $x škodlivé účinky $7 D000068258
650    _2
$a ženské pohlaví $7 D005260
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $x škodlivé účinky $7 D000971
650    12
$a nádory vaječníků $x farmakoterapie $x patologie $7 D010051
650    12
$a maytansin $x analogy a deriváty $x terapeutické užití $x škodlivé účinky $x aplikace a dávkování $7 D008453
650    12
$a folátový receptor 1 $x antagonisté a inhibitory $7 D058975
650    12
$a imunokonjugáty $x terapeutické užití $x škodlivé účinky $x aplikace a dávkování $7 D018796
650    _2
$a humanizované monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D061067
650    _2
$a udržovací chemoterapie $7 D060046
650    _2
$a platina $x terapeutické užití $x aplikace a dávkování $7 D010984
650    _2
$a doba přežití bez progrese choroby $7 D000077982
655    _2
$a časopisecké články $7 D016428
655    _2
$a protokol klinické studie $7 D000078325
700    1_
$a Myers, Tashanna $u Obstetrics and Gynecology, UMass Chan Medical School, Springfield, MA 01199, USA
700    1_
$a Wimberger, Pauline $u Gynecology and Obstetrics, and Gynecological Oncology, Carl Gustav Carus University, Technische Universität Dresden, Dresden, 01307, Germany
700    1_
$a Van Gorp, Toon $u Division of Gynaecological Oncology, University Hospital Leuven, Leuven Cancer Institute, Leuven, BGOG, 3000, Belgium
700    1_
$a Redondo, Andres $u Servicio de Oncología Médica, Hospital Universitario La Paz-IdiPAZ, Madrid, 28046, Spain
700    1_
$a Cibula, David $u Department of Gynaecology, Obstetrics & Neonatology, General University Hospital in Prague & First Faculty of Medicine, Charles University, Prague, 120 00;110 00, Czech Republic
700    1_
$a Nicum, Shibani $u Oncology, University College London Hospitals NHS Foundation Trust, London, NW1 2BU, UK
700    1_
$a Rodrigues, Manuel $u Medical Oncology, Institut Curie., PSL Research University, INSERM U830, Paris, 75006, France
700    1_
$a Backes, Floor J $u Gynecologic Oncology, James Cancer Center/The Ohio State University, Columbus, OH 43210, USA
700    1_
$a Barlin, Joyce N $u Women's Cancer Care Associates, Albany Medical College, Albany, NY 12208, USA
700    1_
$a Lewin, Sharyn N $u Gynecologic Oncology, Holy Name Medical Center, Teaneck, NJ 07666, USA
700    1_
$a Lim, Peter $u Center of Hope, University of Nevada, Reno School of Medicine, Reno, NV 89557, USA
700    1_
$a Pothuri, Bhavana $u Gynecologic Oncology, Perlmutter Cancer Center, NYU Langone Health, New York, NY 10016, USA
700    1_
$a Diver, Elisabeth $u Medical Affairs, ImmunoGen, Inc., Waltham, MA 02451, USA
700    1_
$a Banerjee, Susana $u Gynaecology Unit, The Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London, SW3 6JJ, UK
700    1_
$a Lorusso, Domenica $u Gynaecological Oncology Unit, Catholic University of Rome & Fondazione Policlinico Gemelli IRCCS, Rome, 00168,Italy
773    0_
$w MED00008687 $t Future oncology $x 1744-8301 $g Roč. 20, č. 32 (2024), s. 2423-2436
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39082675 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206110007 $b ABA008
999    __
$a ok $b bmc $g 2263750 $s 1240207
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 20 $c 32 $d 2423-2436 $e 20240731 $i 1744-8301 $m Future oncology $n Future Oncol $x MED00008687
GRA    __
$p ImmunoGen
LZP    __
$a Pubmed-20250121

Find record

Citation metrics

Archiving options